Total surgical removal of the thyroid gland (thyroidectomy) results in a state of permanent iatrogenic hypothyroidism. Chronic administration of levothyroxine sodium (LT4) is the therapeutic gold standard for mimicking endogenous hormone production. However, the restoration of biochemical euthyroidism (TSH and free hormone levels within the reference range) does not always coincide with the complete resolution of systemic symptoms. Many patients continue to experience chronic fatigue, metabolic slowdown, low-grade inflammation, and oxidative stress due to the loss of glandular homeostasis and reduced peripheral deiodinase efficiency (the enzymes responsible for converting synthetic T4 into the biologically active metabolite T3).
Maintaining an optimal biochemical environment requires targeted nutraceutical support. The synergistic use of MOLTITUDO® LUNAE and MOLTITUDO® FERROSA provides the body with the enzymatic cofactors and antioxidants needed to maximize the tissue response to replacement hormone, protecting cells from free radicals and countering inflammation. Both products feature cutting-edge formulations and are 100% vegan, developed with plant-based capsules and free from ingredients of animal origin, perfectly meeting the needs of patients following plant-based diets or seeking the highest purity of ingredients.
PRODUCT_ITEM
Daily Dosage Schedule
To ensure maximum therapeutic efficacy and avoid physicochemical interactions in the intestinal lumen, the products must be taken according to a precise schedule:
· Morning (on an empty stomach): Take the prescribed medication (Levothyroxine sodium). Wait at least 30–60 minutes before eating breakfast or drinking coffee.
· Lunch: Take 1 tablet of MOLTITUDO® LUNAE during or immediately after the meal.
· Dinner: Take 1 tablet of MOLTITUDO® LUNAE during or immediately after the meal.
· Afternoon (or mid-morning—away from thyroid medication): Take 1 plant-based capsule of MOLTITUDO® FERROSA, at least 4 hours before or after levothyroxine.
Clinical Rationale for Synergistic Supplementation
MOLTITUDO® LUNAE: Modulation of Inflammation and Peripheral Conversion
The rationale for administering MOLTITUDO® LUNAE (1 tablet at lunch and 1 tablet at dinner) is the need to counteract oxidative stress and chronic low-grade inflammation, which are frequently associated with postoperative thyroid deficiency.
· Tetrahydrocurcuminoids (140 mg per dose): These are the active metabolites of curcumin, offering significantly greater bioavailability and stability. Scientific research shows that curcumin exerts a powerful systemic protective effect. It combats inflammation by reducing pro-inflammatory cytokines and mediators such as leukotrienes, COX-2, TNFalpha, IFNgamma, IL1beta, and NFkappaB. In hypothyroidism, it acts by modulating superoxide dismutase (SOD) and increasing levels of catalase (CAT), reduced glutathione (GSH), and glutathione peroxidase (GPx). This pool reduces hydroxyl radicals and superoxide anions, protecting peripheral tissues and improving hormone receptor expression.
· Boswellia serrata (500 mg, standardized to 65% boswellic acids): Boswellic acids act as selective inhibitors of the 5-lipoxygenase (5-LOX) enzyme, shutting down the inflammatory cascade. In patients who have undergone thyroidectomy, this extract helps control localized inflammation and supports intestinal mucosal health. A healthy colon is essential for preventing dysbiosis and SIBO, which can impair levothyroxine absorption.
· Bromelain from Pineapple (1000 mg, 2500 GDU): A proteolytic enzyme that promotes the drainage of body fluids, combats tissue edema (common in cases of partial metabolic slowdown), and supports proper microcirculation and gastrointestinal function.
MOLTITUDO® FERROSA: Enzymatic Support and Prevention of Drug Interactions
The decision to include MOLTITUDO® FERROSA (1 capsule daily) addresses the need to correct or prevent deficiencies in micronutrients essential for the metabolic axis, following a strict dosing schedule.
· The 4-Hour Rule (Away from Medication): Traditional iron and calcium supplements form insoluble chemical complexes (chelation) if they come into contact with levothyroxine in the stomach, drastically reducing its absorption and disrupting TSH levels. For this reason, the MOLTITUDO® FERROSA capsule must be taken strictly in the mid-afternoon or at least 4 hours away from the medication.
· Liposomal Pyrophosphate Iron (20 mg): Iron is the essential cofactor for the thyroid peroxidase (TPO) enzyme and peripheral cytochrome systems. There is a close correlation between iron-deficiency anemia and reduced tissue sensitivity to thyroid hormones. MOLTITUDO® FERROSA’s liposomal technology coats the mineral in a phospholipid membrane: this protects it from gastric acidity, eliminates typical side effects (nausea, constipation, gastric heartburn), and maximizes intestinal absorption.
· Selenium (55 micrograms, 100% NRV from L-selenomethionine): It is the essential biological component of deiodinases (D1, D2), the enzymes responsible for converting L4 (levothyroxine) into the active metabolite T3. Without an adequate supply of selenium, the administered medication cannot be effectively activated by peripheral tissues.
· Zinc Gluconate (2.5 mg): Works synergistically with selenium, aiding the synthesis of nuclear thyroid hormone receptors and supporting immune defenses.
· Complete Vitamin Pool (Vitamins C, D3 from lichen, K2, E, B-Complex, Folic Acid): Liposomal Vitamin C enhances iron efficacy; B-Complex vitamins (B1, B2, B6, B12) support cellular energy metabolism, mitigating fatigue; plant-based Vitamin D3 (lichen) and Vitamin K2 support calcium homeostasis, an essential protective factor in cases of transient or permanent postoperative hypoparathyroidism.
PLEASE NOTE: The information provided in the product sheets on this site is for informational and educational purposes only and does not constitute medical advice. The published content is not intended to replace a relationship with a doctor or any medical indications, diagnoses, or prescriptions. The information provided describes the ingredients and characteristics of dietary supplements, designed to support the body’s balance and well-being within a healthy lifestyle. Dietary supplements are not medicines and must not be used to prevent, diagnose, treat, or alleviate diseases or medical conditions.
Bibliographic References
· Bianco, A. C., & da Conceição, R. R. (2018). The deiodinase system and peripheral control of thyroid hormone activation. European Thyroid Journal, 7(Suppl. 1), 14-22. (Study on the biological mechanisms of peripheral hormone activation and the role of selenoproteins).
· Brzezińska-Slebodzińska, E., & Pietras, B. (1997). The role of oxidative stress and antioxidant supplementation in thyroid dysfunction. Journal of Endocrinology Investigations, 20(3), 112-118. (Biological mechanisms of oxidative stress in thyroid dysfunction).
· Farhangi, M. A., Dehghan, P., et al. (2016). The effects of Nigella sativa and antioxidant status on thyroid function. BMC Complementary and Alternative Medicine, 16, 452. (Clinical evidence on the antioxidant modulation of the thyroid microenvironment).
· Jonklaas, J., Bianco, A. C., task force on thyroid hormone replacement, et al. (2014). Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association. Thyroid, 24(12), 1670-1751. (Official guidelines documenting the need to separate the intake of Iron and Calcium from Levothyroxine).
· Panda, S., & Kar, A. (1999). Withania somnifera and Commiphora mukul in the regulation of thyroid function. Journal of Pharmacy and Pharmacology, 51(10), 1199-1202. (Preclinical study on the metabolic activation induced by guggulsterones).
· Rayman, M. P. (2012). Selenium and vitamin D in thyroid disease. Nature Reviews Endocrinology, 8(9), 517-530. (Molecular mechanisms of the action of Selenium and Zinc on muscle and liver deiodinases).
· Shakeri, F., et al. (2022). Curcumin effects on thyroid gland function and oxidative stress markers in Wistar rats: impact of aging. Phytotherapy Research, 36(5), 2105-2115. (Biological study on the effects of curcumin on the reduction of COX-2, TNF-alpha, NFkB and the increase of SOD, CAT, GSH).
· Virili, C., Centanni, M., et al. (2019). Atypical factors affecting L-thyroxine absorption. Frontiers in Endocrinology, 10, 580. (Clinical study on gastric interference factors and the importance of intestinal mucosal integrity).
